CB-03-01, a molecule patented by Cosmo, is a steroidal ester, androgen antagonist derived from 11-deoxycortisone, which tightly mimics the profile of an ideal anti-androgen for topical use.
The objective is to create a product for topical application to treat acne, male pattern baldness, and seborrhoea that does not have the side effects of products currently being taken in tablet form.
An IND was granted in the US for CB-03-01 for acne in Q1 2012. Phase II dose escalating clinical trials were initiated in the US in H2 2012 and are scheduled to be completed in H1 2014. An IND is planned to be filed for alopecia in H1 2014.
CB-03-01 is licensed to Medicis - Valeant for all indications on a world-wide basis.